Cas no for 259793-96-9,6-Fluoro-3-hydroxypyrazine-2-carboxamide ACID Cas number search msds database,online free cas number chemistry search engine,cas number sigma aldrich

Products
Suppliers
Sourcing Requests

Post Sourcing Request Exhibition

Home
Products
Supplier
E-Trade Season
Content Hub
Industry Insights
Service & Membership
For Supplier

My Account

My Online Store

My EZSourcing

View Sourcing Requests

Customer Service
For Buyer

Search Products & Suppliers
Products Directory Suppliers Discovery Post EZSourcing
Service
Buyer Sourcing Event Contact Us
Quick links
My Favorites Recent Visit History

Home > CAS No. Inquiry > 259793-96-9

259793-96-9

[CAS Name] 6-Fluoro-3-hydroxypyrazine-2-carboxamide

[Formula] C5H4FN3O2

Search Products Post Sourcing Request

Basica Info

[CAS Name]6-Fluoro-3-hydroxypyrazine-2-carboxamide
[Alias]T-705
[Number]259793-96-9
[EINECS]
[Formula]C5H4FN3O2
[Molecular weight]

259793-96-9 Suppliers

Company

Main Products

Quanzhou Fortune Biopharma Co.,Ltd.

Favipiravir, as a new broad-spectrum anti-rna virus drug, was approved to be marketed in Japan in March 2014 for the antiviral treatment of influenza a and b.

Research shows that in addition to influenza virus, familavir also shows good antiviral activity against a variety of RNA viruses, such as ebola virus, sand virus, bunya virus, rabies virus.Recent studies have shown that fabivir has a certain inhibitory effect on COVID-19.

Send Inquiry

Hangzhou Bio-Bounce Technology Co., Ltd

Discovered by Toyama Chemical Co., Ltd. in Japan, favipiravir is a modified pyrazine analog that was initially approved for therapeutic use in resistant cases of influenza. The antiviral targets RNA-dependent RNA polymerase (RdRp) enzymes, which are necessary for the transcription and replication of viral genomes. Not only does favipiravir inhibit replication of influenza A and B, but the drug has shown promise in the treatment of avian influenza, and may be an alternative option for influenza strains that are resistant to neuramidase inhibitors. Favipiravir has been investigated for the treatment of life-threatening pathogens such as Ebola virus, Lassa virus, and now COVID-19.

Send Inquiry

Sinoway Industrial Co.Ltd.

99% up by HPLC USP GMP DMF Favipiravir 259793-96-9

Send Inquiry

Previous page 1 2 3 4 5 Next page

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us: About PharmaSources; Terms of Service; Privacy Policy; Intellectual Property; Media Partners

Buy: Search Products; Post Sourcing Requests; Search Suppliers; CAS Search

Sell: Member Application; Advertising; Post Products; EZSourcing

Events: CPHI China; PMEC China; Conferences; Search Events

Help: FAQ; Contact Us; Feedback

Links：
CCCMHPIE SJGLE.com JJGLE.COM JDGLE.COM XIUGLE.COM DENGGLE.COM HPGLE.COM
Follow Us：
Pharma Sources Insight June 2024: Globalization on the Go

PharmaSources Customer Service